Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...
Tandem Diabetes Care, Inc.’s TNDM flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company’s LLY Lyumjev (insulin ...
Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...
SAN DIEGO, May 29, 2024--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...
Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...
Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.
Brown, Dexcom Head of Market Access discusses diabetes management. The views expressed here are not necessarily those of The Scotsman and it is recommended to always seek NHS advice before commencing ...
New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.
Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...
Dexcom designs and commercializes continuous ... and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
While insulin pumps are not quite equivalent to life-saving ... We believe integration with iOS smartphones and the latest CGMs from Dexcom and Abbott should help support top-line growth of ...